Goldman's High Growth Investment Ratio Stocks: EA, AMZN, FANG, Etc
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Gilead Upgraded to Outperform by Leerink on PreEP Outlook
Peering Into Gilead Sciences's Recent Short Interest
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $600 Price Target
Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For HATTR-PN
Market Whales and Their Recent Bets on VRTX Options
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Vertex Coverage Resumed by UBS at Buy on Growth Potential
Looking Into Amgen's Recent Short Interest
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Gilead Sciences Analyst Ratings
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Alnylam Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Jasper Gains 11% on Data for Briquilimab in Urticaria